TGTX TG Therapeutics, Inc.
Healthcare$38.87-0.94%ClosedMarket Cap: $5.95B
As of 2026-05-25
Valuation
P/E (TTM)
11.92
PEG
0.01
P/B
9.63
P/S
8.50
EV/EBITDA
39.92
DCF Value
$-62.74
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.0%
Operating Margin
21.3%
Net Margin
66.0%
ROE
87.4%
ROA
30.2%
ROIC
11.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $204.9M | 83.6% | $34.8M | $19.8M | $— | — |
| Q4 null | $192.6M | 80.2% | $50.5M | $23.0M | $— | — |
| FY null | $616.3M | 83.7% | $123.3M | $447.2M | $— | — |
| Q3 null | $161.7M | 82.6% | $29.4M | $390.9M | $— | — |
| Q2 null | $141.1M | 86.6% | $34.8M | $28.2M | $— | — |
| Q1 null | $120.9M | 87.1% | $8.6M | $5.1M | $— | — |
| Q4 null | $108.2M | 85.8% | $29.9M | $23.3M | $— | — |
| FY null | $329.0M | 88.3% | $41.9M | $23.4M | $— | — |
| Q3 null | $83.9M | 88.9% | $12.4M | $3.9M | $— | — |
| Q2 null | $73.5M | 88.7% | $8.8M | $6.9M | $— | — |
| Q1 null | $63.5M | 91.3% | $-9.3M | $-10.7M | $— | — |
| Q4 2023 | $44.0M | 81.9% | $-12.5M | $-14.4M | $-0.10 | — |